{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:48:51Z","timestamp":1792547331627,"version":"4.5.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bladder cancer kills nearly 170,000 people worldwide each year. Over the past 4 decades, the systematic treatment of metastatic and locally advanced bladder cancer has mainly consisted of platinum-based chemotherapy. In the last 10 years, the development of next-generation sequencing have led to rapid characterization of whole-genome sequencing of bladder cancer, which gives us a better understanding of the pathogenesis of bladder cancer. Based on indications of high mutation burden, and microsatellite instability-high\/deficient mismatch repair, immune checkpoint inhibitors have been studied in metastatic and locally advanced bladder cancer as well as bladder-sparing, and shows a good response in these specific indications. Besides, clinically significant expressed molecular targets are used to develop cancer targeted drugs, such as fibroblast growth factor receptor inhibitors and antibody-drug coupling agents. The exploration of molecular characteristics and subtypes of bladder cancer and the development of new drugs and treatment strategy have also stimulated more clinical studies of bladder cancer. Here, we review advances in the treatment of bladder cancer and clinical practice of next-generation sequencing, highlight important advances in immunotherapy for bladder cancer, preliminarily summarize molecular features of bladder cancer for clinical practice, and came up with direction for future treatment development.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1684597","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:55Z","timestamp":1768973875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Ning","sequence":"first","affiliation":[{"name":"Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengkang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]},{"name":"Department of Urology of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of Chinese People\u2019s Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03376-9","article-title":"Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer","volume":"72","author":"Semeniuk-Wojta\u015b","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2022.10.008","article-title":"Bladder preservation for muscle-invasive bladder cancer with variant histology","volume":"33","author":"Brocklehurst","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00345-006-0061-7","article-title":"Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure","volume":"24","author":"Stein","year":"2006","journal-title":"World J Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2020.99.01","article-title":"Bladder preservation in muscle-invasive bladder cancer: a comprehensive review","volume":"46","author":"Hamad","year":"2020","journal-title":"Int Braz J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2017.12.008","article-title":"Quality of life after radical cystectomy","volume":"45","author":"Tyson","year":"2018","journal-title":"Urol Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S409791","article-title":"Benchmarking maintenance therapy survival in first-line platinum-based chemotherapy-treated patients with advanced urothelial carcinoma using simulated disease modeling","volume":"15","author":"Galsky","year":"2023","journal-title":"Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1570","article-title":"LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer","volume":"7","author":"Dudek","year":"2018","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.01.003","article-title":"Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: A systematic review","volume":"4","author":"de Kruijff","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2257389","article-title":"Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future","volume":"23","author":"Koga","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.056","article-title":"Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: A systematic review and meta-analysis","volume":"97","author":"Vashistha","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0199-x","article-title":"Organ preservation in bladder cancer: an opportunity for truly personalized treatment","volume":"16","author":"Song","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1369565","article-title":"Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators","volume":"57","author":"Boustani","year":"2018","journal-title":"Acta Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601852","article-title":"Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer","volume":"90","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20654","article-title":"Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results","volume":"101","author":"Danesi","year":"2004","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.002","article-title":"Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis","volume":"57","author":"Ramani","year":"2010","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(01)00455-8","article-title":"Distressful symptoms after radical radiotherapy for urinary bladder cancer","volume":"62","author":"Henningsohn","year":"2002","journal-title":"Radiother Oncol"},{"key":"B31","article-title":"Adverse effects of radiation therapy","volume-title":"StatPearls","author":"Majeed","year":"2023"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s40001-023-01408-9","article-title":"Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis","volume":"28","author":"Zhou","year":"2023","journal-title":"Eur J Med Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"496.e17","DOI":"10.1016\/j.urolonc.2021.01.016","article-title":"The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy","volume":"39","author":"Lenis","year":"2021","journal-title":"Urol Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5945","article-title":"Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer","volume":"14","author":"Nguyen","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2017.02.03","article-title":"Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? | Opinion: Yes","volume":"43","author":"Monteiro","year":"2017","journal-title":"Int Braz J Urol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers13010087","article-title":"Review of experimental studies to improve radiotherapy response in bladder cancer: comments and perspectives","volume":"13","author":"Silina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.07.05","article-title":"The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer","volume":"8","author":"Desai","year":"2019","journal-title":"Transl Androl Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-1350","article-title":"Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence","volume":"12","author":"Uccello","year":"2023","journal-title":"Ann Palliat Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02659-w","article-title":"A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics","volume":"23","author":"Zhang","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-017-0549-7","article-title":"Immune checkpoint blockade: the new frontier in cancer treatment","volume":"13","author":"Clarke","year":"2018","journal-title":"Target Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1038\/s41467-021-25103-7","article-title":"An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer","volume":"12","author":"Gouin","year":"2021","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02019-6","article-title":"CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1126247","article-title":"The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"10732748221111296","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218805141","article-title":"Updates and novel treatments in urothelial carcinoma","volume":"25","author":"Hanna","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2022.2118606","article-title":"Immunotherapy for bladder cancer: latest advances and ongoing clinical trials","volume":"51","author":"Ward Grados","year":"2022","journal-title":"Immunol Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.3390\/ijms22062800","article-title":"Improving anti-PD-1\/PD-L1 therapy for localized bladder cancer","volume":"22","author":"de Jong","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","article-title":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment","volume":"35","author":"Zhou","year":"2017","journal-title":"Urol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4574","article-title":"Myeloid cell-associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1822743","article-title":"Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer","volume":"20","author":"Moussa","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"17588359211045858","DOI":"10.1177\/17588359211045858","article-title":"Role of immunotherapy in localized muscle invasive urothelial cancer","volume":"13","author":"Kaur","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"734.e1","DOI":"10.1016\/j.urolonc.2021.06.001","article-title":"PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue","volume":"39","author":"Schulz","year":"2021","journal-title":"Urol Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European association of urology guideline): American society of clinical oncology clinical practice guideline endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"256.e17","DOI":"10.1016\/j.urolonc.2023.02.002","article-title":"Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis","volume":"41","author":"Lee","year":"2023","journal-title":"Urol Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949567","article-title":"Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases","volume":"9","author":"Mao","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12894-022-01083-8","article-title":"Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study","volume":"22","author":"Ren","year":"2022","journal-title":"BMC Urol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.343","article-title":"Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.12.033","article-title":"Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer","volume":"110","author":"Marcq","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1782201","article-title":"The emerging role of antibody-drug conjugates in urothelial carcinoma","volume":"20","author":"Lattanzi","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.02.010","article-title":"The overall survival benefit in EV-302: is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma","volume":"7","author":"Benjamin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/cells8060637","article-title":"Targeting the oncogenic FGF-FGFR axis in gastric carcinogenesis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cells"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201700718","article-title":"Discovery of rogaratinib (BAY 1163877): a pan-FGFR inhibitor","volume":"13","author":"Collin","year":"2018","journal-title":"ChemMedChem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32224","article-title":"Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models","volume":"145","author":"Gr\u00fcnewald","year":"2019","journal-title":"Int J Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3900","article-title":"Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: the FORT-2 phase 1b nonrandomized clinical trial","volume":"10","author":"Sweis","year":"2024","journal-title":"JAMA Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-019-01046-2","article-title":"Status der Verf\u00fcgbarkeit und Anwendung von \u201enext generation sequencing\u201d (NGS) beim Harnblasenkarzinom \u2013 eine Umfrage in der Arbeitsgemeinschaft Uropathologie [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group","volume":"59","author":"Ortiz-Br\u00fcchle","year":"2020","journal-title":"Urologe A"},{"key":"B99","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.patol.2022.09.002","article-title":"PD-L1 immunoexpression and molecular characterization of histological subtypes in urothelial carcinoma","volume":"56","author":"Dawid de Vera","year":"2023","journal-title":"Rev Esp Patol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06069-6","article-title":"The complementarity of DDR, nucleic acids and anti-tumour immunity","volume":"619","author":"Kornepati","year":"2023","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643282","article-title":"Predictive value of the TP53\/PIK3CA\/ATM mutation classifier for patients with bladder cancer responding to immune checkpoint inhibitor therapy","volume":"12","author":"Pan","year":"2021","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J Clin Invest"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00933","article-title":"ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment","volume":"11","author":"Yi","year":"2020","journal-title":"Front Genet"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205216","article-title":"p16","volume":"71","author":"Serra","year":"2018","journal-title":"J Clin Pathol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/genes13050851","article-title":"A novel cuproptosis-related prognostic gene signature and validation of differential expression in clear cell renal cell carcinoma","volume":"13","author":"Bian","year":"2022","journal-title":"Genes (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.808208","article-title":"Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B109","article-title":"Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13072-025-00590-w","article-title":"Chromatin remodeling and cancer: the critical influence of the SWI\/SNF complex","volume":"18","author":"Hao","year":"2025","journal-title":"Epigenet Chromatin"},{"key":"B111","doi-asserted-by":"publisher","first-page":"20230477","DOI":"10.1259\/bjr.20230477","article-title":"E2F3\/CDCA2 reduces radiosensitivity in gastric adenocarcinoma by activating PI3K\/AKT pathway","volume":"96","author":"Gao","year":"2023","journal-title":"Br J Radiol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0305-z","article-title":"miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3","volume":"12","author":"Liu","year":"2014","journal-title":"J Transl Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.3390\/cancers14215433","article-title":"Interplay between tumor mutational burden and mutational profile and its effect on overall survival: A pilot study of metastatic patients treated with immune checkpoint inhibitors","volume":"14","author":"Xavier","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/ijms24021092","article-title":"Mutational landscape of bladder cancer in mexican patients: KMT2D mutations and chr11q15.5 amplifications are associated with muscle invasion","volume":"24","author":"P\u00e9rez-Montiel","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.831146","article-title":"Comparative analysis of differentially mutated genes in non-muscle and muscle-invasive bladder cancer in the Chinese population by whole exome sequencing","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"},{"key":"B116","doi-asserted-by":"publisher","first-page":"108293","DOI":"10.1016\/j.celrep.2020.108293","article-title":"Enhancer reprogramming confers dependence on glycolysis and IGF signaling in KMT2D mutant melanoma","volume":"33","author":"Maitituoheti","year":"2020","journal-title":"Cell Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.03.031","article-title":"Radiomic prediction of CCND1 expression levels and prognosis in low-grade glioma based on magnetic resonance imaging","volume":"31","author":"Zhao","year":"2024","journal-title":"Acad Radiol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/IJPM.IJPM_980_19","article-title":"Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas","volume":"64","author":"Karakaya","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65504","article-title":"CCND1 as a prognostic and diagnostic biomarker and the impact of its epigenetic alterations on cancer survival","volume":"16","author":"Taha","year":"2024","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:57Z","timestamp":1768973877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2025.1684597"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1684597","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1684597"}}